Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DSGN NASDAQ:IDYA NASDAQ:IRON NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$13.54+8.8%$12.27$3.33▼$17.25$843.09M1.63535,563 shs452,703 shsIDYAIDEAYA Biosciences$34.04+9.0%$29.79$20.50▼$39.28$2.99B-0.041.10 million shs946,918 shsIRONDisc Medicine$71.78+1.4%$68.61$40.00▼$99.50$2.74B0.93583,050 shs408,118 shsTARSTarsus Pharmaceuticals$63.23+0.1%$63.18$38.51▼$85.25$2.72B0.49603,145 shs433,736 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics0.00%+13.40%+13.40%+22.32%+232.62%IDYAIDEAYA Biosciences0.00%+7.76%+7.32%-1.30%+44.12%IRONDisc Medicine0.00%+4.12%+5.94%+19.76%+37.16%TARSTarsus Pharmaceuticals0.00%+1.95%+1.45%-1.51%+55.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSGNDesign Therapeutics$13.54+8.8%$12.27$3.33▼$17.25$843.09M1.63535,563 shs452,703 shsIDYAIDEAYA Biosciences$34.04+9.0%$29.79$20.50▼$39.28$2.99B-0.041.10 million shs946,918 shsIRONDisc Medicine$71.78+1.4%$68.61$40.00▼$99.50$2.74B0.93583,050 shs408,118 shsTARSTarsus Pharmaceuticals$63.23+0.1%$63.18$38.51▼$85.25$2.72B0.49603,145 shs433,736 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSGNDesign Therapeutics0.00%+13.40%+13.40%+22.32%+232.62%IDYAIDEAYA Biosciences0.00%+7.76%+7.32%-1.30%+44.12%IRONDisc Medicine0.00%+4.12%+5.94%+19.76%+37.16%TARSTarsus Pharmaceuticals0.00%+1.95%+1.45%-1.51%+55.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSGNDesign Therapeutics 2.88Moderate Buy$16.5021.86% UpsideIDYAIDEAYA Biosciences 2.82Moderate Buy$50.6948.93% UpsideIRONDisc Medicine 2.75Moderate Buy$105.8047.41% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6743.40% UpsideCurrent Analyst Ratings BreakdownLatest DSGN, IRON, TARS, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026IRONDisc Medicine Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$80.00 ➝ $85.006/12/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/10/2026IRONDisc Medicine WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$88.006/2/2026IDYAIDEAYA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.005/22/2026IDYAIDEAYA Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/14/2026IRONDisc Medicine Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $80.005/12/2026DSGNDesign Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/7/2026IDYAIDEAYA Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.005/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.005/4/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.00(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AIDYAIDEAYA Biosciences$218.71M13.67N/AN/A$11.67 per share2.92IRONDisc MedicineN/AN/AN/AN/A$19.52 per shareN/ATARSTarsus Pharmaceuticals$451.36M6.03N/AN/A$8.09 per share7.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)IDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)IRONDisc Medicine-$212.18M-$6.62N/AN/AN/AN/A-36.94%-33.88%8/6/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.14N/A21.65N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest DSGN, IRON, TARS, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million5/5/2026Q1 2026IRONDisc Medicine-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/A4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDSGNDesign TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSGNDesign TherapeuticsN/A22.2822.28IDYAIDEAYA BiosciencesN/A10.7410.74IRONDisc Medicine0.0424.0024.00TARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSGNDesign Therapeutics56.64%IDYAIDEAYA Biosciences98.29%IRONDisc Medicine83.70%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipDSGNDesign Therapeutics17.10%IDYAIDEAYA Biosciences4.70%IRONDisc Medicine3.76%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableIRONDisc Medicine3038.16 million36.73 millionNot OptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableDSGN, IRON, TARS, and IDYA HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Lowered by Wall Street ZenJune 20 at 1:30 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Downgraded by Wall Street Zen to HoldJune 20 at 1:29 AM | marketbeat.comTarsus: Not Cheap, But Xdemvy Makes The Valuation WorkJune 19 at 1:46 AM | seekingalpha.comTarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $183,384.32 in StockJune 18, 2026 | insidertrades.comIshara Investments LP Purchases Shares of 24,000 Tarsus Pharmaceuticals, Inc. $TARSJune 18, 2026 | marketbeat.comCormorant Asset Management LP Lowers Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 18, 2026 | marketbeat.comTarsus Pharmaceuticals Inc.June 16, 2026 | barrons.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Sands Capital Alternatives LLCJune 15, 2026 | marketbeat.comFrazier Life Sciences Management L.P. Sells 438,883 Shares of Tarsus Pharmaceuticals, Inc. $TARSJune 14, 2026 | marketbeat.comA Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived DiscountJune 10, 2026 | finance.yahoo.comClearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARSJune 10, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street ZenJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $29.16 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 5, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 2, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMJohn Cena hops into the ring to fight demodex blepharitis for Tarsus PharmaceuticalsMay 19, 2026 | mmm-online.comMTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 20263 Rate-Ready Stocks for the New Fed Chair’s First Big TestBy Chris Markoch | June 16, 2026DSGN, IRON, TARS, and IDYA Company DescriptionsDesign Therapeutics NASDAQ:DSGN$13.52 +1.08 (+8.69%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.IDEAYA Biosciences NASDAQ:IDYA$34.03 +2.80 (+8.97%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Disc Medicine NASDAQ:IRON$71.78 +0.99 (+1.39%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$63.22 +0.06 (+0.10%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
